Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

Ritedose, a sterile contract manufacturing organisation, is expanding its manufacturing facility with a seventh ...

Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) ...

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

When pressed for 2025 expectations, Verona believed $254 million in revenues was a fair estimate. Critically, Verona expects ...

1 Day VRNA -7.21% DJIA -5.50% S&P 500 -5.97% Health Care/Life Sciences 4.56% ...

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More ...

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.

Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Paolo Zanetti Formation: 3 - 5 - 2 Manager: Cristian Chivu Formation ...

Verona Pharma reported impressive fourth-quarter results, with revenue reaching $35.65 million, significantly exceeding analyst estimates of $6.14 million. This strong performance was driven by the ...